137 related articles for article (PubMed ID: 18662109)
1. Etravirine for the treatment of HIV infection.
Seminari E; Castagna A; Lazzarin A
Expert Rev Anti Infect Ther; 2008 Aug; 6(4):427-33. PubMed ID: 18662109
[TBL] [Abstract][Full Text] [Related]
2. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
[TBL] [Abstract][Full Text] [Related]
4. Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.
Johnson LB; Saravolatz LD
Clin Infect Dis; 2009 Apr; 48(8):1123-8. PubMed ID: 19275497
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Madruga JV; Cahn P; Grinsztejn B; Haubrich R; Lalezari J; Mills A; Pialoux G; Wilkin T; Peeters M; Vingerhoets J; de Smedt G; Leopold L; Trefiglio R; Woodfall B;
Lancet; 2007 Jul; 370(9581):29-38. PubMed ID: 17617270
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of etravirine (TMC125) in patients with highly resistant HIV-1: primary 24-week analysis.
; Nadler JP; Berger DS; Blick G; Cimoch PJ; Cohen CJ; Greenberg RN; Hicks CB; Hoetelmans RM; Iveson KJ; Jayaweera DS; Mills AM; Peeters MP; Ruane PJ; Shalit P; Schrader SR; Smith SM; Steinhart CR; Thompson M; Vingerhoets JH; Voorspoels E; Ward D; Woodfall B
AIDS; 2007 Mar; 21(6):F1-10. PubMed ID: 17413684
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
Lazzarin A; Campbell T; Clotet B; Johnson M; Katlama C; Moll A; Towner W; Trottier B; Peeters M; Vingerhoets J; de Smedt G; Baeten B; Beets G; Sinha R; Woodfall B;
Lancet; 2007 Jul; 370(9581):39-48. PubMed ID: 17617271
[TBL] [Abstract][Full Text] [Related]
8. Etravirine: a review of its use in the management of treatment-experienced patients with HIV-1 infection.
Croxtall JD
Drugs; 2012 Apr; 72(6):847-69. PubMed ID: 22512366
[TBL] [Abstract][Full Text] [Related]
9. Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.
Jayaweera DT; Espinoza L; Castro J
Expert Opin Pharmacother; 2008 Dec; 9(17):3083-94. PubMed ID: 19006480
[TBL] [Abstract][Full Text] [Related]
10. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Hull MW; Montaner JS
Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
[TBL] [Abstract][Full Text] [Related]
11. Etravirine.
Deeks ED; Keating GM
Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
[TBL] [Abstract][Full Text] [Related]
12. Etravirine: R165335, TMC 125, TMC-125, TMC125.
Drugs R D; 2006; 7(6):367-73. PubMed ID: 17073519
[TBL] [Abstract][Full Text] [Related]
13. Etravirine for the treatment of HIV/AIDS.
Schrijvers R
Expert Opin Pharmacother; 2013 Jun; 14(8):1087-96. PubMed ID: 23560740
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
[TBL] [Abstract][Full Text] [Related]
15. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
Vingerhoets J; Tambuyzer L; Azijn H; Hoogstoel A; Nijs S; Peeters M; de Béthune MP; De Smedt G; Woodfall B; Picchio G
AIDS; 2010 Feb; 24(4):503-14. PubMed ID: 20051805
[TBL] [Abstract][Full Text] [Related]
16. [Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
Tian XT; Xie L
Yao Xue Xue Bao; 2010 Feb; 45(2):177-83. PubMed ID: 21351427
[TBL] [Abstract][Full Text] [Related]
17. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
Clotet B; Clumeck N; Katlama C; Nijs S; Witek J
J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782
[TBL] [Abstract][Full Text] [Related]
18. [Etravirine in highly treatment-experienced patients].
Palter DP; Corbera EF; Tiraboschi JM
Enferm Infecc Microbiol Clin; 2009 Dec; 27 Suppl 2():6-11. PubMed ID: 20116622
[TBL] [Abstract][Full Text] [Related]
19. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
20. Etravirine in the treatment of HIV-1: a clinical overview for healthcare professionals.
Yeni P; Mills A; Peeters M; Vingerhoets J; Kakuda TN; De Smedt G; Woodfall B
Curr HIV Res; 2010 Oct; 8(7):564-76. PubMed ID: 20946097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
